Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06343636
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-04-02
First Post:
2024-03-26
Brief Title:
A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimers Disease
Sponsor:
Vigil Neuroscience Inc
Organization:
Vigil Neuroscience Inc
Study Overview
Official Title:
A Phase 1 First-in-human Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer39s Disease to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of VG-3927
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1 First-in-human Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimers Disease to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of VG-3927
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None